3.2. M Stage, Serum S100B, pT Category, Clark Level and Primary Tumor Localization Are Significant and Independent Prognostic Factors of Disease Progression in Metastatic Melanoma Patients Treated with BRAF + MEK Inhibitors. This evidence concerns the gene S100B and melanoma.